Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Desvenlafaxine Succinate
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : Intellipharmaceutics Corporation
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Company has granted Taro an exclusive license to market, sell and distribute in Canada, Desvenlafaxine Extended-release Tablets in the 50 mg and 100 mg strengths approved for sale in the Canadian market by the Pharmaceutical Drugs Directory (PDD) of Heal...
Product Name : Desvenlafaxine-Generic
Product Type : Miscellaneous
Upfront Cash : Undisclosed
August 16, 2022
Lead Product(s) : Desvenlafaxine Succinate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : Intellipharmaceutics Corporation
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Desvenlafaxine Succinate
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of Desvenlafaxine in Treating Major Depressive Disorder.
Details : Desvenlafaxine Succinate is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Depressive Disorder, Major.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 28, 2020
Lead Product(s) : Desvenlafaxine Succinate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Desvenlafaxine Succinate
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of MD-120 in Patients With Depression
Details : Desvenlafaxine is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Depressive Disorder, Major.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 14, 2020
Lead Product(s) : Desvenlafaxine Succinate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable